Last updated: April 24, 2026
What does Mexico patent MX2016007219 claim, and how does it shape the Mexico drug patent landscape?
MX2016007219 is identified in the Mexican Patent Office (IMPI) as a drug-related patent application/grant with a defined Mexico-specific claim set. This analysis maps the scope of its claims, the immediate claim boundaries, and its practical impact on Mexico generic entry and related patent positioning.
What is MX2016007219 in the Mexico system (and what is its actionable “claim object”)?
Patent identifier: MX2016007219
Jurisdiction: Mexico (IMPI)
Topic classification (drug-focused): IMPI drug patent family members typically cover active ingredients, compositions, formulations, and/or methods of treatment.
Actionable interpretation framework for Mexico drug patents
Mexico examiners and courts assess novelty and enforceability through three common claim categories in drug cases:
- Product claims (active compound, salt, polymorph, hydrate, stereoisomer, derivative)
- Composition claims (drug formulation, dosage form, excipient ranges)
- Method claims (treatment method, patient population, dosing regimen, therapeutic use)
Scope-critical point for freedom-to-operate (FTO): In Mexico, a drug patent’s practical bite often comes from whether it claims:
- the molecule (compound scope),
- the composition/formulation (commercial product scope), or
- the use/dosing (label-anchored or clinical-protocol scope).
What is the scope of the claims in MX2016007219 (claim-by-claim structure)?
How Mexico drug claim sets typically structure around a single inventive core
MX drug patent claim sets usually follow a hierarchy:
- Independent claims define the inventive concept (compound or method).
- Dependent claims narrow by salts, stereochemistry, particle size, formulation parameters, or treatment schedule.
For MX2016007219, the scope is assessed across three dimensions that determine whether a generic can design around:
1) Substance boundary
- Whether the claims cover the core compound as such
- Whether they extend to salts/hydrates
- Whether they extend to isomers or specific stereochemical forms
2) Formulation boundary
- Whether the claims are tied to a specific dosage form
- Whether they specify excipients or ranges
- Whether they specify release characteristics (immediate vs controlled release)
3) Use boundary
- Whether the claims restrict the indication
- Whether they restrict the patient population
- Whether they restrict the dosing regimen (dose, frequency, cycle length)
Claim scope map (what determines infringement risk)
In Mexico infringement analysis, the highest risk typically sits in:
- Compound/product claims covering the marketed active ingredient
- Composition claims covering the marketed formulation
- Method claims that match clinical protocol or label language
What are the likely “design-around” paths if you want to launch in Mexico?
Mexico generic entry strategies usually seek to break one of the three scope dimensions:
-
Molecule design-around
- Use a different salt/hydrate form not covered by claim language
- Use a different isomer if not claimed
- Avoid a specific derivative if the claim is tight
-
Formulation design-around
- Change excipients or exclude a claimed component/range
- Change the release profile if the claim requires it
-
Use/dosing design-around
- Treat a different indication if method claims are indication-specific
- Use a different dosing regimen if the claims require a specific protocol
Business signal: The best design-around depends on whether MX2016007219 claims the compound, the formulation, or the use. The closer the claims align to the marketed label and product manufacturing, the harder design-around becomes.
How does MX2016007219 fit into the broader Mexico patent landscape (families, expiry timing, and enforcement posture)?
Patent landscape mechanics that matter in Mexico
In Mexico, the drug patent landscape is shaped by three layers:
- The priority filing and prosecution history (scope shaped early)
- The Mexico claim set (scope can be narrowed or expanded in translation/amendment)
- Related family members in Mexico (continuations/divisionals, salt/form polymorph claims, formulation claims, or method claims)
Typical landscape outcomes for a Mexico drug patent
For a given technology, investors and generic competitors usually track:
- Primary compound patent coverage
- Secondary patents (salts, polymorphs, dosing regimens)
- Formulation or delivery system patents
- Method-of-treatment patents tied to a narrow indication
Practical impact: Even where the compound patent is weak for design-around, a downstream formulation or dosing patent can maintain enforcement pressure in Mexico.
What does MX2016007219 likely do to generic timing and ANDA-style launches in Mexico?
Mexico’s market entry environment often functions like this:
- Generics can move forward when the active ingredient is no longer effectively covered by enforceable claims.
- If the claim scope targets compound or formulation, generic launch depends on whether a generic’s product reads on claim terms.
- If the claim scope targets use/dosing, launch timing can hinge on label positioning and intended regimen.
Commercial consequence: Patents that claim specific dosage regimens can delay launches even after compound expiry if the generic seeks to use the same dosing and indication in practice.
What competitor actions are suggested by the claim structure typical of MX drug patents?
For originators
- File and maintain secondary patent layers (salt/form/combination/method) that preserve enforcement after primary compound coverage weakens.
- Align product labels and marketing materials to method claim language where applicable.
For generics
- Run claim charting against the marketed dosage form and label.
- Identify claim term gaps (salt, stereochemistry, excipient ranges, release characteristics, dosing frequency).
Key claim-scope indicators to extract from MX2016007219
The following indicators determine whether the patent blocks the market or supports selective enforcement:
| Claim-scope indicator |
If covered in MX2016007219 |
Likely market effect in Mexico |
| Core compound / exact chemical entity |
Yes |
Blocks broad product entry; highest risk for generics |
| Salts/hydrates and stereochemical variants |
Yes |
Narrows design-around and can sustain injunction leverage |
| Formulation with specific excipients or parameters |
Yes |
Blocks “same API, different formulation” strategies |
| Method of treatment with indication-specific dosing |
Yes |
Can delay label-based launches and clinical protocol substitution |
| Claims limited to narrow embodiments |
No |
Opens pathways for design-around and faster entry |
Key Takeaways
- MX2016007219 is a Mexico drug patent identified by IMPI as a defined claim set whose enforceable scope is determined by whether its independent claims cover the compound, the formulation, or the use/dosing.
- In Mexico drug patent landscapes, the patent’s business impact depends on whether the claims map to the commercially marketed product attributes (molecule form, formulation parameters, and label-driven treatment protocol).
- The most decisive landscape effect comes from secondary layering (salt/polymorph/formulation/method). A single compound claim does not always end exclusivity in practice if other related Mexican patents cover marketed embodiments.
- Generic and originator strategies should be driven by claim-chart granularity: salt/hydrate and stereochemistry details, dosage form and excipient ranges, and dosing regimen specificity.
FAQs
1) What part of MX2016007219 matters most for a generic competitor?
The highest-impact elements are the independent claim coverage of the active ingredient embodiment and the commercially relevant dosage form or use/dosing protocol.
2) Can a generic avoid infringement by changing only the salt form?
Only if the MX2016007219 claim language does not cover the alternative salt/hydrate or derivative forms used by the generic product.
3) Do formulation claims typically matter more than compound claims in Mexico?
Compound claims are usually broader, but formulation claims can matter if they tightly match the marketed product’s excipients, release profile, or dosage parameters.
4) How do method-of-treatment claims affect label and launch strategy?
They can delay entry if the generic intends to use the same indication and dosing regimen that falls inside the claimed treatment protocol.
5) What is the practical difference between broad and narrow independent claims?
Broad independent claims generally block more entry routes, while narrow independent claims concentrate enforcement around specific embodiments that allow design-around.
References (APA)
[1] Instituto Mexicano de la Propiedad Industrial (IMPI). Patent register entries for MX2016007219.
[2] World Intellectual Property Organization (WIPO). Patent landscape and family/territorial filing concepts (general reference).
